Aaron M Etra, MD
-
- Position
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialties
- Hematology-Oncology
- Cancer (Oncology)
-
- Language
- English
-
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai Morningside and Mount Sinai West
-
- Phone
- Ruttenberg Treatment Center 212-241-6021 212-241-6021
-
Ruttenberg Treatment Center
1470 Madison Avenue
3rd Floor
New York, NY 10029
Phone: 212-241-6021212-241-6021
Aaron Etra, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and a member of The Tisch Cancer Institute. His clinical practice focus is on autologous and allogeneic stem cell transplantation for acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, bone marrow failure syndromes, lymphoma, and multiple myeloma. Dr. Etra provides evidence-based care that is compassionate and patient-centered.
Dr. Etra’s research interests include acute graft-versus-host disease (aGVHD), a primary cause of non-relapse mortality following allogeneic stem cell transplantation, and infectious complications post-transplant. He is a member of the Mount Sinai Acute GVHD International Consortium (MAGIC), which promotes development and testing of innovative treatment approaches for aGVHD.
Dr. Etra is an investigator on numerous clinical trials, including MAGIC observational studies and trials that investigate novel agents for both low-risk and high-risk GVHD. He is the site principal investigator at Mount Sinai for trials of the Blood and Marrow Transplant Clinical Trials Network that are focused on developing tools for predicting non-relapse mortality in transplant patients and identifying improved GVHD prophylaxis and treatment regimens.
Certifications
Hematology
Medical Oncology
American Board of Internal Medicine
Education
MD, Albert Einstein College of Medicine
Internship, Internal Medicine
Beth Israel Medical Center
Residency, Internal Medicine
Mount Sinai Beth Israel
Fellowship, Hematology-Oncology
Mount Sinai Hospital
Language
English
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Etra during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Olson Research Group, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.